Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 6281054, 19 pages
https://doi.org/10.1155/2018/6281054
Review Article

Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management

1Nephrology Department, Centre Hospitalier Universitaire de Bruxelles (CHUB), Brugmann Hospital, Brussels, Belgium
2Université Libre de Bruxelles (ULB), Brussels, Belgium
3Pathology Department, AP-HP, Pitié Hospital, Paris, France
4UPMC Université Paris 6, Paris, France
5Centre National de Référence Maladies Rares: Amylose AL et Autres Maladies à Dépôts d’Immunoglobulines Monoclonales, Université de Poitiers, Poitiers, France
6Pathology Department, Centre Hospitalier Universitaire de Poitiers, Poitiers, France
7Nephrology Department, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium

Correspondence should be addressed to Agnieszka Pozdzik; eb.nnamgurb-uhc@kizdzop.akzseinga

Received 11 June 2017; Revised 31 August 2017; Accepted 15 October 2017; Published 8 January 2018

Academic Editor: Michael Mahler

Copyright © 2018 Agnieszka Pozdzik et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Debiec, V. Guigonis, B. Mougenot et al., “Brief report: Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies,” The New England Journal of Medicine, vol. 346, no. 26, pp. 2053–2060, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. H. Debiec, F. Lefeu, M. J. Kemper et al., “Early-childhood membranous nephropathy due to cationic bovine serum albumin,” The New England Journal of Medicine, vol. 364, no. 22, pp. 2101–2110, 2011. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Debiec, V. Valayannopoulos, O. Boyer et al., “Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: A need for tolerance induction therapy,” Journal of the American Society of Nephrology, vol. 25, no. 4, pp. 675–680, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. L. H. Beck Jr., R. G. B. Bonegio, G. Lambeau et al., “M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy,” The New England Journal of Medicine, vol. 361, no. 1, pp. 11–21, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. N. M. Tomas, L. H. Beck Jr., C. Meyer-Schwesinger et al., “Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy,” The New England Journal of Medicine, vol. 371, no. 24, pp. 2277–2287, 2014. View at Publisher · View at Google Scholar
  6. Y. Du, J. Li, F. He et al., “The diagnosis accuracy of PLA2R-AB in the diagnosis of idiopathic membranous nephropathy: A meta-analysis,” PLoS ONE, vol. 9, no. 8, Article ID e104936, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Iwakura, N. Ohashi, A. Kato, S. Baba, and H. Yasuda, “Prevalence of enhanced granular expression of thrombospondin type-1 domain-containing 7A in the Glomeruli of Japanese patients with idiopathic membranous nephropathy,” PLoS ONE, vol. 10, no. 9, Article ID e0138841, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Akiyama, M. Akiyama, E. Imai, T. Ozaki, S. Matsuo, and S. Maruyama, “Prevalence of anti-phospholipase A2 receptor antibodies in Japanese patients with membranous nephropathy,” Clinical and Experimental Nephrology, vol. 19, no. 4, pp. 653–660, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. C. P. Larsen, L. N. Cossey, and L. H. Beck, “THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity,” Modern Pathology, vol. 29, no. 4, pp. 421–426, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. D. C. Cattran and P. E. Brenchley, “Membranous nephropathy: integrating basic science into improved clinical management,” Kidney International, vol. 91, no. 3, pp. 566–574, 2017. View at Publisher · View at Google Scholar
  11. P. Ronco and H. Debiec, “Pathophysiological advances in membranous nephropathy: Time for a shift in patient's care,” The Lancet, vol. 385, no. 9981, pp. 1983–1992, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Francis, L. H. Beck, and D. J. Salant, “Membranous Nephropathy: A Journey from Bench to Bedside,” American Journal of Kidney Diseases, vol. 68, no. 1, pp. 138–147, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. J. M. Hofstra, H. Debiec, C. D. Short et al., “Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy,” Journal of the American Society of Nephrology, vol. 23, no. 10, pp. 1735–1743, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. J. M. Hofstra and J. F. M. Wetzels, “Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues,” Journal of the American Society of Nephrology, vol. 25, no. 6, pp. 1137–1139, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Kanigicherla, J. Gummadova, E. A. McKenzie et al., “Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy,” Kidney International, vol. 83, no. 5, pp. 940–948, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Beck, A. S. Bomback, M. J. Choi et al., “KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis,” American Journal of Kidney Diseases, vol. 62, no. 3, pp. 403–441, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. E. Hoxha, L. H. Beck, T. Wiech et al., “An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain–containing 7A–specific antibodies in membranous nephropathy,” Journal of the American Society of Nephrology, vol. 28, no. 2, pp. 520–531, 2017. View at Publisher · View at Google Scholar
  18. D. T. Erwin, J. V. Donadio Jr., and K. E. Holley, “The clinical course of idiopathic membranous nephropathy,” Mayo Clinic Proceedings, vol. 48, no. 10, pp. 697–712, 1973. View at Google Scholar · View at Scopus
  19. R. J. Glassock, “Pathogenesis of membranous nephropathy: a new paradigm in evolution,” Contributions to Nephrology, vol. 181, pp. 131–142, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. W. C. Chan and Y. C. Tsao, “Diffuse membranous glomerulonephritis in children,” Journal of Clinical Pathology, vol. 19, no. 5, pp. 464–469, 1966. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Menon and R. P. Valentini, “Membranous nephropathy in children: clinical presentation and therapeutic approach,” Pediatric Nephrology, vol. 25, no. 8, pp. 1419–1428, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Ronco and H. Debiec, “Advances in membranous nephropathy: Success stories of a long journey,” Clinical and Experimental Pharmacology and Physiology, vol. 38, no. 7, pp. 410–416, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Hofstra, L. H. Beck Jr., D. M. Beck, J. F. Wetzels, and D. J. Salant, “Anti-phospholipase A2 receptor antibodies correlate with clinical status in idiopathic membranous nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 6, pp. 1286–1291, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Ronco and H. Debiec, “Pathogenesis of membranous nephropathy: Recent advances and future challenges,” Nature Reviews Nephrology, vol. 8, no. 4, pp. 203–213, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Ruggenenti and G. Remuzzi, “Idiopathic membranous nephropathy: back to the future?” The Lancet, vol. 381, no. 9868, pp. 706–708, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. R. Mactier, B. Jones, C. D. Payton, and A. McLay, “The natural history of membranous nephropathy in the west of Scotland,” QJM: An International Journal of Medicine, vol. 60, no. 2, pp. 793–802, 1986. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Toth and S. Takebayashi, “Idiopathic membranous glomerulonephritis: a clinicopathologic and quantitative morphometric study,” Clinical Nephrology, vol. 38, no. 1, pp. 14–19, 1992. View at Google Scholar · View at Scopus
  28. G. R. Briefel, T. Manis, D. H. Gordon, A. D. Nicastri, and E. A. Friedman, “Recurrent renal vein thrombosis consequent to membranous glomerulonephritis,” Clinical Nephrology, vol. 10, no. 1, pp. 32–37, 1978. View at Google Scholar · View at Scopus
  29. R. D. Wagoner, A. W. Stanson, K. E. Holley, and C. S. Winter, “Renal vein thrombosis in idiopathic membranous glomerulopathy and nephrotic syndrome: incidence and significance,” Kidney International, vol. 23, no. 2, pp. 368–374, 1983. View at Publisher · View at Google Scholar · View at Scopus
  30. T. H. Tran, G. J. Hughes, C. Greenfeld, and J. T. Pham, “Overview of current and alternative therapies for idiopathic membranous nephropathy,” Pharmacotherapy, vol. 35, no. 4, pp. 396–411, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. H. Huh, H. Lee, J. P. Lee et al., “Factors affecting the long-term outcomes of idiopathic membranous nephropathy,” BMC Nephrology, vol. 18, no. 1, article 104, 2017. View at Publisher · View at Google Scholar · View at Scopus
  32. C. C. Mok, “Membranous nephropathy in systemic lupus erythematosus: a therapeutic enigma,” Nature Reviews Nephrology, vol. 5, no. 4, pp. 212–220, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. E. F. Rodriguez, S. H. Nasr, C. P. Larsen, S. Sethi, M. E. Fidler, and L. D. Cornell, “Membranous nephropathy with crescents: a series of 19 cases,” American Journal of Kidney Diseases, vol. 64, no. 1, pp. 66–73, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Ronco and H. Debiec, “Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy,” Journal of the American Society of Nephrology, vol. 21, no. 4, pp. 564–569, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Yang, Y.-P. Ma, D.-P. Chen, L. Zhuo, and W.-G. Li, “A meta-analysis of antiviral therapy for hepatitis B virus-associated membranous nephropathy,” PLoS ONE, vol. 11, no. 9, Article ID e0160437, 2016. View at Publisher · View at Google Scholar · View at Scopus
  36. Q. Weng, X. Li, H. Ren et al., “Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature,” Oncotarget, vol. 8, no. 13, pp. 22299–22303, 2017. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Taton, K. Moreau, S. Lepreux et al., “Hepatitis E virus infection as a new probable cause of de novo membranous nephropathy after kidney transplantation,” Transplant Infectious Disease, vol. 15, no. 6, pp. E211–E215, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. B. Thajudeen, S. G. John, N.-O. Ossai, I. B. Riaz, E. Bracamonte, and A. N. Sussman, “Membranous nephropathy with crescents in a patient with hashimoto's thyroiditis: a case report,” Medicine, vol. 93, no. 8, article 98, 2014. View at Publisher · View at Google Scholar · View at Scopus
  39. K. N. Miyata, H. Kihira, M. Haneda, and Y. Nishio, “IgG4-related tubulointerstitial nephritis associated with membranous nephropathy in two patients: remission after administering a combination of steroid and mizoribine,” Case Reports in Nephrology, vol. 2014, pp. 1–6, 2014. View at Publisher · View at Google Scholar
  40. J. A. Jefferson and W. G. Couser, “Therapy of membranous nephropathy associated with malignancy and secondary causes,” Seminars in Nephrology, vol. 23, no. 4, pp. 400–405, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Collister, C. Sathianathan, K. Ryz, M. Karpinski, K. Bernstein, and I. W. Gibson, “ANCA associated vasculitis secondary to levamisole-adultered cocaine with associated membranous nephropathy: a case series,” American Journal of Nephrology, vol. 45, no. 3, pp. 209–216, 2017. View at Publisher · View at Google Scholar · View at Scopus
  42. R. P. S. Kumar, N. S. Prasad, S. Tirumavalavan, and M. E. Fernando, “D-penicillamine-induced membranous nephropathy,” Indian Journal of Nephrology, vol. 24, no. 3, pp. 195-196, 2014. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Manabe, M. Banno, M. Nakano et al., “Bucillamine-induced membranous nephropathy with crescent formation in a patient with rheumatoid arthritis: case report and literature review,” Case Reports in Nephrology and Dialysis, vol. 5, no. 1, pp. 30–38, 2015. View at Publisher · View at Google Scholar · View at Scopus
  44. F. A. Nawaz, C. P. Larsen, and M. L. Troxell, “Membranous nephropathy and nonsteroidal anti-inflammatory agents,” American Journal of Kidney Diseases, vol. 62, no. 5, pp. 1012–1017, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Knehtl, H. Debiec, P. Kamgang et al., “A case of phospholipase A2 receptor-positive membranous nephropathy preceding sarcoid-associated granulomatous tubulointerstitial nephritis,” American Journal of Kidney Diseases, vol. 57, no. 1, pp. 140–143, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Stehlé, D. Joly, P. Vanhille et al., “Clinicopathological study of glomerular diseases associated with sarcoidosis: A multicenter study,” Orphanet Journal of Rare Diseases, vol. 8, article 65, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. B. Svobodova, E. Honsova, P. Ronco, V. Tesar, and H. Debiec, “Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy,” Nephrology Dialysis Transplantation , vol. 28, no. 7, pp. 1839–1844, 2013. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Stehlé, J.-J. Boffa, P. Lang, D. Desvaux, D. Sahali, and V. Audard, “Kidney involvement in sarcoidosis,” La Revue de Médecine Interne, vol. 34, no. 9, pp. 538–544, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. T. Stehlé, V. Audard, P. Ronco, and H. Debiec, “Phospholipase A2 receptor and sarcoidosis-associated membranous nephropathy,” Nephrology Dialysis Transplantation , vol. 30, no. 6, pp. 1047–1050, 2015. View at Publisher · View at Google Scholar
  50. A. Gedalia, T. A. Khan, A. K. Shetty, V. R. Dimitriades, and L. R. Espinoza, “Childhood sarcoidosis: Louisiana experience,” Clinical Rheumatology, vol. 35, no. 7, pp. 1879–1884, 2016. View at Publisher · View at Google Scholar · View at Scopus
  51. C. J. Byrne-Dugan, A. B. Collins, A. Q. Lam, and I. Batal, “Membranous nephropathy as a manifestation of graft-versus-host disease: Association with HLA antigen typing, phospholipase A2 receptor, and C4d,” American Journal of Kidney Diseases, vol. 64, no. 6, pp. 987–993, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Abudayyeh, L. D. Truong, L. H. Beck, D. M. Weber, K. Rezvani, and M. Abdelrahim, “Membranous nephropathy in autologous hematopoietic stem cell transplant: Autologous graft-versus-host disease or autoimmunity induction?” Clinical Kidney Journal, vol. 8, no. 4, pp. 440–444, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Zheng, Y. Xiao, Y. Yao et al., “Comparison of urinary biomarkers for early detection of acute kidney injury after cardiopulmonary bypass surgery in infants and young children,” Pediatric Cardiology, vol. 34, no. 4, pp. 880–886, 2013. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Omokawa, A. Komatsuda, M. Nara et al., “Distribution of glomerular IgG subclass deposits in patients with membranous nephropathy and anti-U1 ribonucleoprotein antibody.,” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, vol. 27, no. 5, pp. 1937–1941, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Doi, M. Mayumi, K. Kanatsu, F. Suehiro, and Y. Hamashima, “Distribution of IgG subclasses in membranous nephropathy,” Clinical & Experimental Immunology, vol. 58, no. 1, pp. 57–62, 1984. View at Google Scholar · View at Scopus
  56. L.-H. Noël, P. Aucouturier, R. C. Monteiro, J.-L. Preud'homme, and P. Lesavre, “Glomerular and serum immunoglobulin G subclasses in membranous nephropathy and anti-glomerular basement membrane nephritis,” Clinical Immunology and Immunopathology, vol. 46, no. 2, pp. 186–194, 1988. View at Publisher · View at Google Scholar · View at Scopus
  57. R. Hiramatsu, Y. Ubara, N. Sawa et al., “Clinicopathological analysis of allogeneic hematopoietic stem cell transplantation-related membranous glomerulonephritis,” Human Pathology, vol. 50, pp. 187–194, 2016. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Ohtani, H. Wakui, A. Komatsuda et al., “Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy,” Nephrology Dialysis Transplantation , vol. 19, no. 3, pp. 574–579, 2004. View at Publisher · View at Google Scholar · View at Scopus
  59. Z. Qu, G. Liu, J. Li et al., “Absence of glomerular IgG4 deposition in patients with membranous nephropathy may indicate malignancy,” Nephrology, Dialysis, Transplantation: Official Publication of The European Dialysis and Transplant Association—European Renal Association, vol. 27, no. 5, pp. 1931–1937, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. J. Lönnbro-Widgren, K. Ebefors, J. Mölne, J. Nyström, and B. Haraldsson, “Glomerular IgG subclasses in idiopathic and malignancy-associated membranous nephropathy,” Clinical Kidney Journal, vol. 8, no. 4, pp. 433–439, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. H.-R. Dong, Y.-Y. Wang, X.-H. Cheng et al., “Retrospective study of phospholipase A2 receptor and IgG subclasses in glomerular deposits in Chinese patients with membranous nephropathy,” PLoS ONE, vol. 11, no. 5, Article ID e0156263, 2016. View at Publisher · View at Google Scholar · View at Scopus
  62. S. Asmandar, M.-L. Figuères, J.-M. Goujon, L.-H. Noël, and A. Hummel, “Diagnostic value of IgG subtypes in membranous nephropathy: A case report,” Néphrologie & Thérapeutique, vol. 11, no. 3, article 780, pp. 169–172, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Omokawa, A. Komatsuda, M. Hirokawa, and H. Wakui, “Membranous nephropathy with monoclonal IgG4 deposits and associated IgG4-related lung disease,” Clinical Kidney Journal, vol. 7, no. 5, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. C. Lefaucheur, B. Stengel, and D. Nochy, “Membranous nephropathy and cancer: epidemiologic evidence and determinants of high-risk cancer association,” Kidney International, vol. 70, no. 8, pp. 1510–1517, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. B. Alnasrallah, J. F. Collins, and L. J. Zwi, “Malignancy in Membranous Nephropathy: Evaluation of Incidence,” International Journal of Nephrology, vol. 2017, Article ID 8409829, pp. 1–7, 2017. View at Publisher · View at Google Scholar
  66. R. Hirschberg and S. Wang, “Proteinuria and growth factors in the development of tubulointerstitial injury and scarring in kidney disease,” Current Opinion in Nephrology and Hypertension, vol. 14, no. 1, pp. 43–52, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. K. Zandi-Nejad, A. A. Eddy, R. J. Glassock, and B. M. Brenner, “Why is proteinuria an ominous biomarker of progressive kidney disease?” Kidney International Supplements, vol. 66, no. 92, pp. S76–S89, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. E. Hoxha, S. Harendza, H. Pinnschmidt, U. Panzer, and R. A. K. Stahl, “M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 9, no. 11, pp. 1883–1890, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. T. Takano, H. Elimam, and A. V. Cybulsky, “Complement-mediated cellular injury,” Seminars in Nephrology, vol. 33, no. 6, pp. 586–601, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. F. C. Fervenza, G. Downer, L. H. Beck Jr., and S. Sethi, “IgG4-related tubulointerstitial nephritis with membranous nephropathy,” American Journal of Kidney Diseases, vol. 58, no. 2, pp. 320–324, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Ma, D. G. Sandor, and L. H. Beck, “The role of complement in membranous nephropathy,” Seminars in Nephrology, vol. 33, no. 6, pp. 531–542, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. P. Ronco and H. Debiec, “Membranous nephropathy: a fairy tale for immunopathologists, nephrologists and patients,” Molecular Immunology, vol. 68, no. 1, pp. 57–62, 2015. View at Publisher · View at Google Scholar
  73. P. Ronco, H. Debiec, and V. Guigonis, “Mechanisms of Disease: Alloimmunization in renal diseases,” Nature Clinical Practice Nephrology, vol. 2, no. 7, pp. 388–397, 2006. View at Publisher · View at Google Scholar · View at Scopus
  74. B. M. Coupes, S. P. Kon, P. E. C. Brenchley, C. D. Short, and N. P. Mallick, “The temporal relationship between urinary c5b-9 and c3dg and clinical parameters in human membranous nephropathy,” Nephrology Dialysis Transplantation , vol. 8, no. 5, pp. 397–401, 1993. View at Publisher · View at Google Scholar · View at Scopus
  75. A. A. Papagianni, E. Alexopoulos, M. Leontsini, and M. Papadimitriou, “C5b-9 and adhesion molecules in human idiopathic membranous nephropathy,” Nephrology Dialysis Transplantation , vol. 17, no. 1, pp. 57–63, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. W. J. Liu, Z. Li, X. Chen et al., “Blockage of the lysosome-dependent autophagic pathway contributes to complement membrane attack complex-induced podocyte injury in idiopathic membranous nephropathy,” Scientific Reports, vol. 7, article 8643, 2017. View at Publisher · View at Google Scholar
  77. M. Beeken, M. T. Lindenmeyer, S. M. Blattner et al., “Alterations in the ubiquitin proteasome system in persistent but not reversible proteinuric diseases,” Journal of the American Society of Nephrology, vol. 25, no. 11, pp. 2511–2525, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. A. V. Cybulsky, “The intersecting roles of endoplasmic reticulum stress, ubiquitin-proteasome system, and autophagy in the pathogenesis of proteinuric kidney disease,” Kidney International, vol. 84, no. 1, pp. 25–33, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. C. Meyer-Schwesinger, T. N. Meyer, H. Sievert et al., “Ubiquitin C-terminal hydrolase-L1 activity induces polyubiquitin accumulation in podocytes and increases proteinuria in rat membranous nephropathy,” The American Journal of Pathology, vol. 178, no. 5, pp. 2044–2057, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. L. Biancone, S. David, V. Della Pietra, G. Montrucchio, V. Cambi, and G. Camussi, “Alternative pathway activation of complement by cultured human proximal tubular epithelial cells,” Kidney International, vol. 45, no. 2, pp. 451–460, 1994. View at Publisher · View at Google Scholar · View at Scopus
  81. G. Camussi, M. Rotunno, G. Segoloni, J. R. Brentjens, and G. A. Andres, “In vitro alternative pathway activation of complement by the brush border of proximal tubules of normal rat kidney,” The Journal of Immunology, vol. 128, no. 4, pp. 1659–1663, 1982. View at Google Scholar · View at Scopus
  82. A. Zaferani, R. R. Vivès, P. Van Der Pol et al., “Identification of tubular heparan sulfate as a docking platform for the alternative complement component properdin in proteinuric renal disease,” The Journal of Biological Chemistry, vol. 286, no. 7, pp. 5359–5367, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Harboe, C. Johnson, S. Nymo et al., “Properdin binding to complement activating surfaces depends on initial C3b deposition,” Proceedings of the National Acadamy of Sciences of the United States of America, vol. 114, no. 4, pp. E534–E539, 2017. View at Publisher · View at Google Scholar · View at Scopus
  84. H. Gaarkeuken, M. A. Siezenga, K. Zuidwijk et al., “Complement activation by tubular cells is mediated by properdin binding,” American Journal of Physiology-Renal Physiology, vol. 295, no. 5, pp. F1397–F1403, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. P. Ronco and H. Debiec, “Molecular pathomechanisms of membranous nephropathy: From heymann nephritis to alloimmunization,” Journal of the American Society of Nephrology, vol. 16, no. 5, pp. 1205–1213, 2005. View at Publisher · View at Google Scholar · View at Scopus
  86. N. M. Tomas, E. Hoxha, A. T. Reinicke et al., “Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy,” The Journal of Clinical Investigation, vol. 126, no. 7, pp. 2519–2532, 2016. View at Publisher · View at Google Scholar · View at Scopus
  87. C.-Y. Chen, G. Salles, M. F. Seldin, A. E. Kister, E. L. Reinherz, and M. A. Shipp, “Murine common acute lymphoblastic leukemia antigen (CD10 neutral endopeptidase 24.11): Molecular characterization, chromosomal localization, and modeling of the active site,” The Journal of Immunology, vol. 148, no. 9, pp. 2817–2825, 1992. View at Google Scholar · View at Scopus
  88. P. Hu, Q. Xuan, B. Hu, L. Lu, and Y. H. Qin, “Anti-neutral endopeptidase, natriuretic peptides disarrangement, and proteinuria onset in membranous nephropathy,” Molecular Biology Reports, vol. 40, no. 4, pp. 2963–2967, 2013. View at Publisher · View at Google Scholar · View at Scopus
  89. J. L. Nortier, H. Debiec, Y. Tournay et al., “Neonatal disease in neutral endopeptidase alloimmunization: Lessons for immunological monitoring,” Pediatric Nephrology, vol. 21, no. 10, pp. 1399–1405, 2006. View at Publisher · View at Google Scholar · View at Scopus
  90. H. Debiec, J. Nauta, F. Coulet et al., “Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies,” The Lancet, vol. 364, no. 9441, pp. 1252–1259, 2004. View at Publisher · View at Google Scholar · View at Scopus
  91. H. Debiec, V. Guigonis, B. Mougenot et al., “Extra-membranous glomerulonephritis: report of a family and new physiopathological concepts,” Bulletin de L'academie Nationale De Medecine, vol. 187, no. 5, pp. 921–932, 2003. View at Google Scholar
  92. M. Vivarelli, F. Emma, T. Pellé et al., “Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies,” Kidney International, vol. 87, no. 3, pp. 602–609, 2015. View at Publisher · View at Google Scholar · View at Scopus
  93. C. Murtas, L. Allegri, and G. M. Ghiggeri, “Circulating antipodocyte antibodies in membranous nephropathy: New findings,” American Journal of Kidney Diseases, vol. 62, no. 1, pp. 12–15, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. R. Ramachandran, V. Kumar, A. Kumar et al., “PLA2R antibodies, glomerular PLA2R deposits and variations in PLA2R1 and HLA-DQA1 genes in primary membranous nephropathy in South Asians,” Nephrology Dialysis Transplantation , vol. 31, no. 9, pp. 1486–1493, 2016. View at Publisher · View at Google Scholar · View at Scopus
  95. G. Gupta, H. Fattah, R. Ayalon et al., “Pre-transplant phospholipase A2 receptor autoantibody concentration is associated with clinically significant recurrence of membranous nephropathy post-kidney transplantation,” Clinical Transplantation, vol. 30, no. 4, pp. 461–469, 2016. View at Publisher · View at Google Scholar · View at Scopus
  96. A. Behnert, M. J. Fritzler, B. Teng et al., “An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor,” PLoS ONE, vol. 8, no. 4, Article ID e61669, 2013. View at Publisher · View at Google Scholar · View at Scopus
  97. G. Sugahara, J. Kamiie, R. Kobayashi, T. Mineshige, and K. Shirota, “Expression of phospholipase A2 receptor in primary cultured podocytes derived from dog kidneys,” Journal of Veterinary Medical Science, vol. 78, no. 5, pp. 895–899, 2016. View at Publisher · View at Google Scholar · View at Scopus
  98. H. Debiec, M. Hanoy, A. Francois et al., “Recurrent membranous nephropathy in an allograft caused by IgG3κ targeting the PLA2 receptor,” Journal of the American Society of Nephrology, vol. 23, no. 12, pp. 1949–1954, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. P. T. Klouda, E. J. Acheson, F. S. Goldby et al., “Strong association between idiopathic membranous nephropathy and HLA-DRW3,” The Lancet, vol. 314, no. 8146, pp. 770-771, 1979. View at Publisher · View at Google Scholar · View at Scopus
  100. S. Mezzano, G. Rojas, L. Ardiles et al., “Idiopathic membranous nephropathy, associated with HLA-DRw3 and not related to monocyte-phagocyte system Fc receptor dysfunction, in father and son,” Nephron, vol. 58, no. 3, pp. 320–324, 1991. View at Publisher · View at Google Scholar · View at Scopus
  101. H. C. Stanescu, M. Arcos-Burgos, A. Medlar et al., “Risk HLA-DQA1 and PLA2R1 alleles in idiopathic membranous nephropathy,” The New England Journal of Medicine, vol. 364, no. 7, pp. 616–626, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. S. Kim, H. J. Chin, K. Y. Na et al., “Single nucleotide polymorphisms in the phospholipase A2 receptor gene are associated with genetic susceptibility to idiopathic membranous nephropathy,” Nephron Clinical Practice, vol. 117, no. 3, pp. c253–c258, 2011. View at Publisher · View at Google Scholar · View at Scopus
  103. G. Bullich, J. Ballarín, A. Oliver et al., “HLA-DQA1 and PLA2R1 polymorphisms and risk of idiopathic membranous nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 9, no. 2, pp. 335–343, 2014. View at Publisher · View at Google Scholar · View at Scopus
  104. Y.-H. Liu, C.-H. Chen, S.-Y. Chen et al., “Association of phospholipase A2 receptor 1 polymorphisms with idiopathic membranous nephropathy in Chinese patients in Taiwan,” Journal of Biomedical Science, vol. 17, article 81, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. P. Ruggenenti, H. Debiec, B. Ruggiero et al., “Anti-Phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy,” Journal of the American Society of Nephrology, vol. 26, no. 10, pp. 2545–2558, 2015. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Fresquet, T. A. Jowitt, and J. Gummadova, “Identification of a major epitope recognized by PLA2R autoantibodies in primary membranous nephropathy,” Journal of the American Society of Nephrology, vol. 26, no. 2, pp. 302–313, 2015. View at Publisher · View at Google Scholar
  107. L. Kao, V. Lam, M. Waldman, R. J. Glassock, and Q. Zhu, “Identification of the immunodominant epitope region in phospholipase A2 receptor-mediating autoantibody binding in idiopathic membranous nephropathy,” Journal of the American Society of Nephrology, vol. 26, no. 2, pp. 291–301, 2015. View at Publisher · View at Google Scholar
  108. B. Seitz-Polski, G. Dolla, C. Payre et al., “Epitope spreading of autoantibody response to PLA2R associates with poor prognosis in membranous nephropathy,” Journal of the American Society of Nephrology, vol. 27, no. 5, pp. 1517–1533, 2016. View at Publisher · View at Google Scholar
  109. B. Seitz-Polski, G. Lambeau, and V. Esnault, “Membranous nephropathy: Pathophysiology and natural history,” Nephrologie & Therapeutique, vol. 13, supplement 1, pp. S75–S81, 2017. View at Google Scholar
  110. A. Pozdzik, I. Beukinga, C. Gu-Trantien, K. Willard-Gallo, J. Nortier, and O. Pradier, “Circulating (CD3-CD19+CD20-IgD-CD27highCD38high) plasmablasts: a promising cellular biomarker for immune activity for anti-PLA2R1 related membranous nephropathy?” Mediators of Inflammation, vol. 2016, Article ID 7651024, pp. 1–10, 2016. View at Publisher · View at Google Scholar · View at Scopus
  111. M. Rosenzwajg, E. Languille, H. Debiec et al., “B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab,” Kidney International, vol. 92, no. 1, pp. 227–237, 2016. View at Publisher · View at Google Scholar · View at Scopus
  112. D. Roccatello, S. Sciascia, D. Di Simone et al., “New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: a prospective study and a review of the literature,” Autoimmunity Reviews, vol. 15, no. 6, pp. 529–538, 2016. View at Publisher · View at Google Scholar · View at Scopus
  113. A. Barbari, “Pre- and posttransplant refractory idiopathic membranous glomerulonephritis: the forgotten potential culprit,” Experimental and Clinical Transplantation, vol. 15, no. 5, pp. 483–489, 2017. View at Publisher · View at Google Scholar
  114. L. Lin, W. M. Wang, X. X. Pan et al., “Biomarkers to detect membranous nephropathy in Chinese patients,” Oncotarget , vol. 7, no. 42, pp. 67868–67879, 2016. View at Publisher · View at Google Scholar
  115. E. Hoxha, S. Harendza, H. O. Pinnschmidt et al., “Spontaneous remission of proteinuria is a frequent event in phospholipase A2 receptor antibody-negative patients with membranous nephropathy,” Nephrology Dialysis Transplantation , vol. 30, no. 11, pp. 1862–1869, 2015. View at Publisher · View at Google Scholar · View at Scopus
  116. J. Wang, Z. Cui, J. Lu et al., “Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 12, no. 10, pp. 1642–1651, 2017. View at Publisher · View at Google Scholar
  117. E. Hoxha, T. Wiech, P. R. Stahl et al., “A mechanism for cancer-associated membranous nephropathy,” The New England Journal of Medicine, vol. 374, no. 20, pp. 1995-1996, 2016. View at Publisher · View at Google Scholar · View at Scopus
  118. P. R. Stahl, E. Hoxha, T. Wiech, C. Schröder, R. Simon, and R. A. K. Stahl, “THSD7A expression in human cancer,” Genes, Chromosomes and Cancer, vol. 56, no. 4, pp. 314–327, 2017. View at Publisher · View at Google Scholar · View at Scopus
  119. N. D. Quach, J. N. Mock, N. E. Scholpa et al., “Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells,” Molecular Pharmaceutics, vol. 11, no. 10, pp. 3443–3451, 2014. View at Publisher · View at Google Scholar · View at Scopus
  120. J.-G. Lee, S.-H. Lee, D.-W. Park et al., “Toll-like receptor 9-stimulated monocyte chemoattractant protein-1 is mediated via JNK-cytosolic phospholipase A2-ROS signaling,” Cellular Signalling, vol. 20, no. 1, pp. 105–111, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. E. Chiricozzi, S. Fernandez-Fernandez, V. Nardicchi, A. Almeida, J. P. Bolaños, and G. Goracci, “Group IIA secretory phospholipase A2 (GIIA) mediates apoptotic death during NMDA receptor activation in rat primary cortical neurons,” Journal of Neurochemistry, vol. 112, no. 6, pp. 1574–1583, 2010. View at Publisher · View at Google Scholar · View at Scopus
  122. Y. Pan, J. Wan, Y. Liu et al., “sPLA2 IB induces human podocyte apoptosis via the M-type phospholipase A2 receptor,” Scientific Reports, vol. 4, article no. 6660, 2014. View at Publisher · View at Google Scholar · View at Scopus
  123. J. E. Murphy-Ullrich and E. H. Sage, “Revisiting the matricellular concept,” Matrix Biology, vol. 37, pp. 1–14, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. C. Meyer-Schwesinger, G. Lambeau, and R. A. K. Stahl, “The authors reply: Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy,” The New England Journal of Medicine, vol. 372, no. 11, pp. 1074-1075, 2015. View at Publisher · View at Google Scholar · View at Scopus
  125. M. Gödel, F. Grahammer, and T. B. Huber, “Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy,” The New England Journal of Medicine, vol. 372, no. 11, article 1073, 2015. View at Publisher · View at Google Scholar · View at Scopus
  126. N. M. Tomas, C. Meyer-Schwesinger, H. von Spiegel et al., “A heterologous model of thrombospondin type 1 domain-containing 7A-associated membranous nephropathy,” Journal of the American Society of Nephrology, vol. 28, no. 10, 2017. View at Publisher · View at Google Scholar
  127. H. Debiec and P. Ronco, “PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy,” The New England Journal of Medicine, vol. 364, no. 7, pp. 689-690, 2011. View at Publisher · View at Google Scholar · View at Scopus
  128. H. Debiec, L. Martin, C. Jouanneau et al., “Autoantibodies specific for the phospholipase A 2 receptor in recurrent and de novo membranous nephropathy,” American Journal of Transplantation, vol. 11, no. 10, pp. 2144–2152, 2011. View at Publisher · View at Google Scholar · View at Scopus
  129. F. Pourcine, K. Dahan, F. Mihout et al., “Prognostic value of PLA2R autoimmunity detected by measurement of anti-PLA2R antibodies combined with detection of PLA2R antigen in membranous nephropathy: A single-centre study over 14 years,” PLoS ONE, vol. 12, no. 3, Article ID e0173201, 2017. View at Publisher · View at Google Scholar · View at Scopus
  130. E. Hoxha, U. Kneiler, G. Stege et al., “Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy,” Kidney International, vol. 82, no. 7, pp. 797–804, 2012. View at Publisher · View at Google Scholar · View at Scopus
  131. W. Qin, L. H. Beck Jr., C. Zeng et al., “Anti-phospholipase A2 receptor antibody in membranous nephropathy,” Journal of the American Society of Nephrology, vol. 22, no. 6, pp. 1137–1143, 2011. View at Publisher · View at Google Scholar · View at Scopus
  132. K. Hihara, M. Iyoda, S. Tachibana et al., “Anti-phospholipase A2 receptor (PLA2R) antibody and glomerular PLA2R expression in Japanese patients with membranous nephropathy,” PLoS ONE, vol. 11, no. 6, Article ID e0158154, 2016. View at Publisher · View at Google Scholar · View at Scopus
  133. R. Hu, G. Xing, H. Wu, and Z. Zhang, “Clinicopathological features of idiopathic membranous nephropathy combined with IgA nephropathy: A retrospective analysis of 9 cases,” Diagnostic Pathology, vol. 11, no. 1, article 86, 2016. View at Publisher · View at Google Scholar · View at Scopus
  134. Q. Xie, Y. Li, J. Xue et al., “Renal Phospholipase A2 Receptor in Hepatitis B Virus-Associated Membranous Nephropathy,” American Journal of Nephrology, vol. 41, no. 4-5, pp. 345–353, 2015. View at Publisher · View at Google Scholar · View at Scopus
  135. L. H. Beck Jr., F. C. Fervenza, D. M. Beck et al., “Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy,” Journal of the American Society of Nephrology, vol. 22, no. 8, pp. 1543–1550, 2011. View at Publisher · View at Google Scholar · View at Scopus
  136. J. Wang, Q. Xie, Z. Sun et al., “Response to immunosuppressive therapy in PLA2R- associated and non-PLA2R- associated idiopathic membranous nephropathy: a retrospective, multicenter cohort study,” BMC Nephrology, vol. 18, no. 1, article 227, 2017. View at Publisher · View at Google Scholar
  137. E. Hoxha, I. Thiele, G. Zahner, U. Panzer, S. Harendza, and R. A. K. Stahl, “Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy,” Journal of the American Society of Nephrology, vol. 25, no. 6, pp. 1357–1366, 2014. View at Publisher · View at Google Scholar
  138. C. P. Larsen and P. D. Walker, “Phospholipase A2 receptor (PLA2R) staining is useful in the determination of de novo versus recurrent membranous glomerulopathy,” Transplantation, vol. 95, no. 10, pp. 1259–1262, 2013. View at Publisher · View at Google Scholar · View at Scopus
  139. H. Saito, Y. Hamasaki, A. Tojo, Y. Shintani, A. Shimizu, and M. Nangaku, “Phospholipase A2 receptor positive membranous nephropathy long after living donor kidney transplantation between identical twins,” Nephrology, vol. 20, no. 2, pp. 101–104, 2015. View at Publisher · View at Google Scholar · View at Scopus
  140. A. Grupper, L. D. Cornell, F. C. Fervenza, L. H. Beck, E. Lorenz, and F. G. Cosio, “Recurrent Membranous Nephropathy after Kidney Transplantation: Treatment and Long-Term Implications,” Transplantation, vol. 100, no. 12, pp. 2710–2716, 2016. View at Publisher · View at Google Scholar · View at Scopus
  141. C. D. Blosser, R. Ayalon, R. Nair, C. Thomas, and L. H. Beck Jr., “Very early recurrence of anti-phospholipase A 2 receptor-positive membranous nephropathy after transplantation,” American Journal of Transplantation, vol. 12, no. 6, pp. 1637–1642, 2012. View at Publisher · View at Google Scholar · View at Scopus
  142. H. Wakui, H. Imai, A. Komatsuda, and A. B. Miura, “Circulating antibodies against α-enolase in patients with primary membranous nephropathy (MN),” Clinical & Experimental Immunology, vol. 118, no. 3, pp. 445–450, 1999. View at Publisher · View at Google Scholar · View at Scopus
  143. Y. Kimura, N. Miura, H. Debiec et al., “Circulating antibodies to α-enolase and phospholipase A2 receptor and composition of glomerular deposits in Japanese patients with primary or secondary membranous nephropathy,” Clinical and Experimental Nephrology, vol. 21, no. 1, pp. 117–126, 2017. View at Publisher · View at Google Scholar
  144. M. Prunotto, M. L. Carnevali, G. Candiano et al., “Autoimmunity in membranous nephropathy targets aldose reductase and SOD2,” Journal of the American Society of Nephrology, vol. 21, no. 3, pp. 507–519, 2010. View at Publisher · View at Google Scholar · View at Scopus
  145. M. Gödel and T. B. Huber, “Immunosuppression for membranous nephropathy,” The Lancet, vol. 381, no. 9884, article 2161, 2013. View at Publisher · View at Google Scholar · View at Scopus
  146. J. M. Hofstra, F. C. Fervenza, and J. F. M. Wetzels, “Treatment of idiopathic membranous nephropathy,” Nature Reviews Nephrology, vol. 9, no. 8, pp. 443–458, 2013. View at Publisher · View at Google Scholar · View at Scopus
  147. C. Ponticelli and R. J. Glassock, “Glomerular diseases: membranous nephropathy-a modern view,” Clinical Journal of the American Society of Nephrology, vol. 9, no. 3, pp. 609–616, 2014. View at Publisher · View at Google Scholar · View at Scopus
  148. J. Radhakrishnan and D. C. Cattran, “The KDIGO practice guideline on glomerulonephritis: Reading between the (guide)lines-application to the individual patient,” Kidney International, vol. 82, no. 8, pp. 840–856, 2012. View at Publisher · View at Google Scholar · View at Scopus
  149. H. Shiiki, T. Saito, Y. Nishitani et al., “Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan,” Kidney International, vol. 65, no. 4, pp. 1400–1407, 2004. View at Publisher · View at Google Scholar · View at Scopus
  150. R. Dikow, P. Quentmeier, V. Schwenger et al., “Optimal blood pressure control versus additional immunosuppressive therapy in idiopathic membranous nephropathy - A retrospective analysis,” Clinical Nephrology, vol. 72, no. 5, pp. 366–372, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. J. Xu, X. Hu, J. Xie, and N. Chen, “Management of Membranous Nephropathy in Asia,” Kidney Diseases, vol. 1, no. 2, pp. 119–125, 2015. View at Publisher · View at Google Scholar
  152. T. Alfaadhel and D. Cattran, “Management of Membranous Nephropathy in Western Countries,” Kidney Diseases, vol. 1, no. 2, pp. 126–137, 2015. View at Publisher · View at Google Scholar
  153. D. C. Cattran, “Management of membranous nephropathy,” Minerva Urologica e Nefrologica, vol. 54, no. 1, pp. 19–27, 2002. View at Google Scholar
  154. J. A. J. G. van den Brand, P. R. Van Dijk, J. M. Hofstra, and J. F. M. Wetzels, “Long-term outcomes in idiopathic membranous nephropathy using a restrictive treatment strategy,” Journal of the American Society of Nephrology, vol. 25, no. 1, pp. 150–158, 2014. View at Publisher · View at Google Scholar · View at Scopus
  155. D. A. Kanigicherla, C. D. Short, S. A. Roberts et al., “Long-term outcomes of persistent disease and relapse in primary membranous nephropathy,” Nephrology Dialysis Transplantation , vol. 31, no. 12, pp. 2108–2114, 2016. View at Publisher · View at Google Scholar
  156. Y. Chen, A. Schieppati, X. Chen et al., “Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome,” Cochrane Database of Systematic Reviews, vol. 10, article CD004293, 2014. View at Publisher · View at Google Scholar · View at Scopus
  157. M. Praga, “Tacrolimus in membranous nephropathy,” Kidney International, vol. 74, no. 6, article 824, 2008. View at Publisher · View at Google Scholar · View at Scopus
  158. M. Praga, V. Barrio, G. F. Juárez, and J. Luño, “Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trial,” Kidney International, vol. 71, no. 9, pp. 924–930, 2007. View at Publisher · View at Google Scholar · View at Scopus
  159. R. Ramachandran, H. K. Hn, V. Kumar et al., “Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial,” Nephrology, vol. 21, no. 2, pp. 139–146, 2016. View at Publisher · View at Google Scholar · View at Scopus
  160. S. Ren, Y. Wang, L. Xian et al., “Comparative effectiveness and tolerance of immunosuppressive treatments for idiopathic membranous nephropathy: A network meta-analysis,” PLoS ONE, vol. 12, no. 9, p. e0184398, 2017. View at Publisher · View at Google Scholar
  161. X. Yu, L. Ruan, Z. Qu et al., “Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety,” Renal Failure, vol. 39, no. 1, pp. 688–697, 2017. View at Publisher · View at Google Scholar
  162. G. Xie, J. Xu, C. Ye et al., “Immunosuppressive Treatment for Nephrotic Idiopathic Membranous Nephropathy: A Meta-Analysis Based on Chinese Adults,” PLoS ONE, vol. 7, no. 9, Article ID e44330, 2012. View at Publisher · View at Google Scholar · View at Scopus
  163. A. J. Branten, P. W. du Buf-Vereijken, M. Vervloet, and J. F. Wetzels, “Mycophenolate Mofetil in Idiopathic Membranous Nephropathy: A Clinical Trial With Comparison to a Historic Control Group Treated With Cyclophosphamide,” American Journal of Kidney Diseases, vol. 50, no. 2, pp. 248–256, 2007. View at Publisher · View at Google Scholar · View at Scopus
  164. C. Ponticelli, “What is the role of rituximab in idiopathic membranous nephropathy?” Expert Review of Clinical Immunology, vol. 9, no. 1, pp. 13–16, 2013. View at Publisher · View at Google Scholar · View at Scopus
  165. M. A. Hladunewich, D. Cattran, L. H. Beck et al., “A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar Gel) in nephrotic syndrome due to idiopathic membranous nephropathy,” Nephrology Dialysis Transplantation, vol. 29, no. 8, pp. 1570–1577, 2014. View at Publisher · View at Google Scholar · View at Scopus
  166. R. Stahl, E. Hoxha, and K. Fechner, “PLA2R autoantibodies and recurrent membranous nephropathy after transplantation,” The New England Journal of Medicine, vol. 363, no. 5, pp. 496–498, 2010. View at Publisher · View at Google Scholar · View at Scopus
  167. P. Cravedi, G. Remuzzi, and P. Ruggenenti, “Rituximab in primary membranous nephropathy: first-line therapy, why not?” Nephron Clinical Practice, vol. 128, no. 3-4, pp. 261–269, 2014. View at Publisher · View at Google Scholar · View at Scopus
  168. K. Dahan, H. Debiec, E. Plaisier et al., “Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up,” Journal of the American Society of Nephrology, vol. 28, no. 1, pp. 348–358, 2017. View at Publisher · View at Google Scholar
  169. M. Fiorentino, F. Tondolo, F. Bruno et al., “Treatment with rituximab in idiopathic membranous nephropathy,” Clinical Kidney Journal, vol. 9, no. 6, pp. 788–793, 2016. View at Publisher · View at Google Scholar
  170. F. B. Cortazar, D. E. Leaf, C. T. Owens, K. Laliberte, W. F. Pendergraft, and J. L. Niles, “Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series,” BMC Nephrology, vol. 18, no. 1, pp. 1–10, 2017. View at Publisher · View at Google Scholar · View at Scopus
  171. J. A. van den Brand, P. Ruggenenti, A. Chianca et al., “Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy,” Journal of the American Society of Nephrology, vol. 28, no. 9, pp. 2729–2737, 2017. View at Publisher · View at Google Scholar
  172. T. Katsuno, T. Ozaki, H. Kim et al., “Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience,” Internal Medicine, vol. 56, no. 13, pp. 1679–1686, 2017. View at Publisher · View at Google Scholar
  173. F. C. Fervenza, P. A. Canetta, S. J. Barbour et al., “A multicenter randomized controlled trial of rituximab versus cyclosporine in the treatment of idiopathic membranous nephropathy (mentor),” Nephron, vol. 130, no. 3, pp. 159–168, 2015. View at Publisher · View at Google Scholar · View at Scopus
  174. P. Cravedi, “Rituximab in Membranous Nephropathy: Not All Studies Are Created Equal,” Nephron, vol. 135, no. 1, pp. 46–50, 2017. View at Publisher · View at Google Scholar · View at Scopus
  175. W. Cheungpasitporn, S. L. Kopecky, U. Specks, K. Bharucha, and F. C. Fervenza, “Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy,” Journal of Renal Injury Prevention, vol. 6, no. 1, pp. 18–25, 2017. View at Publisher · View at Google Scholar
  176. R. Radhakrishnan, G. Basu, R. George, H. Parmar, and V. Tamilarasi, “Rituximab-induced urticarial dermatitis during the treatment of membranous nephropathy,” Saudi Journal of Kidney Diseases and Transplantation, vol. 28, no. 3, pp. 657–660, 2017. View at Publisher · View at Google Scholar
  177. A. A. Rigler, A. Jerman, A. Orsag et al., “Rituximab for the treatment of membranous nephropathy: a single-center experience,” Clinical Nephrology, vol. 88, no. 13, pp. 27–31, 2017. View at Publisher · View at Google Scholar
  178. G. Moroni, F. Depetri, L. Del Vecchio et al., “Low-dose rituximab is poorly effective in patients with primary membranous nephropathy,” Nephrology, Dialysis, Transplantation: Official Publication of The European Dialysis and Transplant Association - European Renal Association, vol. 32, no. 10, pp. 1691–1696, 2017. View at Publisher · View at Google Scholar
  179. M. Waldman, L. H. Beck, M. Braun, K. Wilkins, J. E. Balow, and H. A. Austin, “Membranous Nephropathy: Pilot Study of a Novel Regimen Combining Cyclosporine and Rituximab,” Kidney International Reports, vol. 1, no. 2, pp. 73–84, 2016. View at Publisher · View at Google Scholar · View at Scopus
  180. A. Barbari, R. Chehadi, H. Kfoury Assouf et al., “Bortezomib as a Novel Approach to Early Recurrent Membranous Glomerulonephritis After Kidney Transplant Refractory to Combined Conventional Rituximab Therapy,” Experimental And Clinical Transplantation: Official Journal of The Middle East Society for Organ Transplantation, vol. 15, no. 3, pp. 350–354, 2017. View at Publisher · View at Google Scholar
  181. G. La Manna, O. Baraldi, V. Cunia et al., “Membranous glomerulonephritis (MGN), ongoing studies,” Giornale Italiano Di Nefrologia, vol. 34, no. 5, pp. 113–118, 2017. View at Google Scholar
  182. P. Ruggenenti, F. C. Fervenza, and G. Remuzzi, “Treatment of membranous nephropathy: time for a paradigm shift,” Nature Reviews Nephrology, vol. 13, no. 9, pp. 563–579, 2017. View at Publisher · View at Google Scholar
  183. J.-F. Cambier and P. Ronco, “Onco-nephrology: glomerular diseases with cancer,” Clinical journal of the American Society of Nephrology, vol. 7, no. 10, pp. 1701–1712, 2012. View at Publisher · View at Google Scholar · View at Scopus
  184. A. S. De Vriese, R. J. Glassock, K. A. Nath, S. Sethi, and F. C. Fervenza, “A Proposal for a serology-based approach to membranous nephropathy,” Journal of the American Society of Nephrology, vol. 28, no. 2, pp. 421–430, 2017. View at Publisher · View at Google Scholar
  185. W. G. Couser, “Primary Membranous Nephropathy,” Clinical Journal of the American Society of Nephrology, vol. 12, no. 6, pp. 983–997, 2017. View at Publisher · View at Google Scholar